Novartis AG’s breakthrough CANCER therapy that works on re-engineered T Cells has won FDA approval. Wednesday was a historic day for Cancer treatment with Novartis announcing FDA approval of Kymriah suspension for intravenous fusion or known as CAR-T (First Chimeric Antigen Receptor T cell).
The therapy will be helpful for patients upto 25 years of age with B-cell precursor acute lymphoblastic lukemia (ALL) that is in refractory or in second or later relapse.
In the CAR-T treatment T-cells are collected from the patient and then infused back into the patient to attach cancer cells.
According to the Novartis media release there has been a need for treatment for patients suffering from relapsed or refractory B-cell precursor ALL. Furthermore, patients undergo multiple treatments including chemotherapy, radiation, targeted therapy, or stem transplant. However, only 10% patients survive five years.
Based on clinical trials the study has shown to find 83% efficacy (Complete Remission or Complete Remission with incomplete blood count recovery) within the 95% confidence interval range.
The approval is an enormous breakthrough in Cancer treatment.